Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The endolysosomal compartment is a dynamic network of membrane-bound organelles, including endosomes and lysosomes, responsible for the sorting, trafficking, and degradation of macromolecules [1]. It serves as a central hub for cellular metabolism and nutrient sensing, primarily through the recruitment of the mTORC1 complex to the lysosomal membrane [2]. This system facilitates the uptake of extracellular materials via endocytosis and the recycling of intracellular components through autophagy [1]. Dysregulation of the endolysosomal pathway is a hallmark of several pathologies, including lysosomal storage disorders and neurodegenerative diseases like Alzheimer's and Parkinson's [3]. In these conditions, the failure of the compartment to degrade proteins or lipids leads to toxic cellular accumulation [3]. Additionally, many viruses, such as SARS-CoV-2 and Ebola, exploit this compartment as a primary entry point into the host cell [4]. Pharmacological strategies often involve lysosomotropic agents that alter the luminal pH or small molecules designed to stabilize resident enzymes [4]. However, because it represents a broad cellular system rather than a single protein or receptor, it is generally considered a cellular location or pathway rather than a discrete therapeutic target [5]. Sources: [1] Huotari, J., & Helenius, A. (2011). Endosome maturation. EMBO J. [2] Saxton, R. A., & Sabatini, D. M. (2017). mTOR Signaling in Growth, Metabolism, and Disease. Cell. [3] Nixon, R. A. (2017). The role of the endolysosomal system in Alzheimer's disease. Nat Rev Neurosci. [4] Kaufmann, A. M., & Krise, J. P. (2007). Lysosomotropic drugs: Mechanisms and implications. J Pharm Sci. [5] Winckler, B., et al. (2018). The endolysosomal system at a glance. J Cell Biol.
Modulation of luminal pH, inhibition of endosomal acidification, substrate reduction therapy, or enzyme replacement therapy within the compartment.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endolysosomal compartment.